| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -25.1 | -14.2 |
| EPS (diluted, $ a share) | $-0.54 | $-0.52 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NYSE: ANRO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Alto Neuroscience, Inc.: key numbers
- Share price
- $24.91Close, Nov 17
- Market cap
- $999M
- Shares outstanding
- 40.11MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Alto Neuroscience, Inc.
All →Alto Neuroscience Financial Results
Alto Neuroscience reported financial results for the third quarter ended September 30, 2026, highlighting a cash position of $319.8 million following a $100 million financing. The company confirmed its clinical pipeline remains on track, with topline data for its PACE-1 trial in treatment-resistant depression expected in the second half of 2027.
“During the third quarter, we continued to advance our clinical programs and strengthened our financial position ahead of a milestone-rich 2027. PACE-1 remains on track, and our recent financing has enabled us to expand the ALTO-207 Phase 3 development plans to include both monotherapy and adjunctive trials, aimed at supporting a broad label in TRD.”
Amit Etkin, M.D., Ph.D., founder and chief executive officer
Alto Neuroscience President and CFO Nicholas Conrad Smith Sells $3.57M of Stock
Nicholas Conrad Smith, President and CFO, sold 134,886 shares of Alto Neuroscience, Inc. at $25.78 to $26.87 a share (average $26.45) in 3 transactions, worth $3.57M in total between Sep 29, 2026 and Sep 30, 2026. Shares held after the trade: 24,060 (-3.6%).
- Value
- $3.57M
- Shares
- 134,886
- Average price
- $26.45
- Role
- President and CFO
- Holding change
- -3.6%
- Trade date
- Sep 29, 2026 to Sep 30, 2026